Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 9/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160904 | 0.89 | CNKSR1 (0.50) | CNKSR1AKT1L3MBTL1HPGDKDM4E | |
| SCHEMBL15811504 | 0.84 | CNKSR1 (0.81) | CNKSR1AKT1ALDH1A1 | |
| SCHEMBL18160885 | 0.79 | CNKSR1 (0.75) | CNKSR1AKT1ALDH1A1 | |
| SCHEMBL18160906 | 0.76 | CNKSR1 (0.44) | CNKSR1AKT1L3MBTL1 | |
| SCHEMBL19867362 | 0.74 | CNKSR1 (0.47) | CNKSR1AKT1L3MBTL1HPGDKDM4E | |
| SCHEMBL17211652 | 0.73 | CNKSR1 (0.85) | CNKSR1AKT1ALDH1A1 | |
| SCHEMBL15811518 | 0.73 | CNKSR1 (1.00) | CNKSR1AKT1ALDH1A1 | |
| SCHEMBL17211718 | 0.73 | CNKSR1 (0.64) | CNKSR1AKT1ALDH1A1 | |
| SCHEMBL15811560 | 0.72 | STAT3 (0.43) | CNKSR1AKT1HPGDKDM4ELMNA | |
| SCHEMBL17211661 | 0.71 | CNKSR1 (0.63) | CNKSR1AKT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885AKT1 780/4885L3MBTL1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.